A New Generation of Serotype Chimeric Infectivity-Enhanced Conditionally Replicative Adenovirals: The Safety Profile of Ad5/3-Δ24 in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients-Reference-Cited by-同舟云学术

A New Generation of Serotype Chimeric Infectivity-Enhanced Conditionally Replicative Adenovirals: The Safety Profile of Ad5/3-Δ24 in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients

Published:2011-07 Issue:7 Volume:22 Page:821-828
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Kim Kenneth H.¹,Ryan Michael J.²,Estep James E.²,Miniard Brock M.²,Rudge Thomas L.²,Peggins James O.³,Broadt Trevor L.⁴,Wang Minghui⁵,Preuss Meredith A.⁵,Siegal Gene P.⁶,Hemminki Akseli⁷,Harris Raymond D.⁸,Aurigemma Rosemarie⁹,Curiel David T.⁵,Alvarez Ronald D.¹

Affiliation:

1. Division of Gynecologic Oncology, University of Alabama at Birmingham, South Birmingham, AL 35249.

2. Battelle Biomedical Research Center, West Jefferson, OH 43162.

3. Toxicology and Pharmacology Branch, National Cancer Institute, Frederick, MD 21702.

4. Quality Control, Biopharmaceutical Development Program, SAIC-Frederick, Inc, NCI-Frederick, Frederick, MD 21702.

5. Division of Human Gene Therapy, University of Alabama at Birmingham, South Birmingham, AL 35249.

6. Department of Pathology, University of Alabama at Birmingham, South Birmingham, AL 35249.

7. Cancer Gene Therapy Group, Molecular Cancer Biology Program, Transplantation Laboratory, Haartman Institute, Finnish Institute for Molecular Medicine, University of Helsinki, and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland.

8. Virology Research & Development Laboratory, Biopharmaceutical Development Program, SAIC-Frederick, Inc, NCI-Frederick, Frederick, MD 21702.

9. Biological Resources Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/hum.2010.180

Reference23 articles.

1. An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism

2. Erratum: Corrigendum

3. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy;Frontiers in Immunology;2023-02-27

2. Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model;Pharmaceutics;2021-04-14

3. Delivery and Biosafety of Oncolytic Virotherapy;Frontiers in Oncology;2020-04-16

4. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents;Journal of Ovarian Research;2019-02-15

5. Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses;Cancers;2019-02-08